Off-label use: The case of methylphenidate;Off-label-use: Der fall methylphenidat

Psychoneuro

Volumn 29, Issue 6, 2003, Pages 302-304

  Fritze, Jürgen ^a   Schmauß, Max ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EQUASIM; LAMOTRIGINE; MEDIKINET; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; DRUG LABELING; DRUG USE; HUMAN; SHORT SURVEY;

EID: 0038152916     PISSN: 16119991     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40491     Document Type: Short Survey

References (5)

1. Dorrego MF, Canevaro L, Kuzis G, Sabe L, Starkstein SE. A randomized, double blind, crossover study of methylphenidate and lithium in adults with attention deficit/hyperactivity disorder: Preliminary findings. J Neuropsychiatry Clin Neurosci 2002; 14: 289-295
2. Krause], Ryffel Rawak D. Therapie der Aufmerksamkeits defizit/Hyperaktivitätsstörung im Erwachsenenalter. Psycho 2000; 26: 209-223
3. Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever Stille KA, Arndt S, Holman TL, Moser DJ, Paulsen JS. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001; 13: 129-134
4. Schubiner H, Saules KK, Arfken CL, Johanson C E, Schuster CR, Lockhart N, Edwards A, Donlin J, Pihlgren E. Double blind placebo controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacology 2002; 10: 286-294
5. The European Agency for the Evaluation of Medicinal Products (EMEA). Note for guidance on clinical investigation of medicinal products in children, 1997